Offering multiple PrEP options, including the dapivirine ring, to young women at reproductive health clinics
Official title: Multi-product PrEP Delivery to Young Women Seeking Reproductive Health Services and Coverage of HIV Prevention
Run by University of Alabama at Birmingham · NCT07076043 · Data updated 2026-11-12
This program will try offering both daily oral PrEP and the dapivirine vaginal ring to women aged 18–30 who come for reproductive health services to see if more start and keep using HIV prevention.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 30 Years |
| Sex | Women only |
| Enrollment | 1400 (estimated) |
| Sponsor | University of Alabama at Birmingham Academic / other |
| Locations | 1 site (Thika, Kiambu County) |
| Status | Recruiting |
| Started | June 3, 2025 |
| Main results expected | December 30, 2028 |
| Study ends | December 30, 2029 |
| Registry record updated | July 22, 2026 |
| Trial ID | NCT07076043 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women aged 18 to 30 who are seeking reproductive health services at one of the participating clinics in Kiambu County, can consent, and can speak Kiswahili or English are the intended participants.
✕Probably not a fit
People younger than 18 or older than 30, those not attending participating clinics, those unwilling or unable to consent, or individuals with medical contraindications to PrEP products may not benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This stepped-wedge cluster randomized program will roll out a multi-product PrEP delivery model across 12 health clinics in Kiambu County, Kenya, enrolling about 1,400 adolescent girls and young women seeking reproductive health services. Clinics will be supported to add the dapivirine vaginal ring alongside existing daily oral PrEP services, and implementation will be staggered so sites transition from standard care to the multi-product offering over time. The primary outcome is whether making multiple PrEP products available increases initiation and persistence of HIV prevention among participants. Data will be collected during routine clinic visits and follow-up to compare uptake and continuation before and after the intervention at each site.
Why it matters
Potential benefit: If successful, offering multiple PrEP options could increase uptake and longer-term use of HIV prevention among young women, lowering their risk of acquiring HIV.
How similar studies have gone: Widespread rollout of daily oral PrEP has shown real-world benefit and the dapivirine ring demonstrated protective effects in prior trials, but integrating multiple PrEP products into routine reproductive health services using a stepped-wedge design is less commonly tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria for Adolescent Girls and Young Women seeking reproductive health services: Age ≥18 years and ≤30years. Seeking a reproductive health service from one of the project facilities (reproductive health services include but are not limited to family planning, maternal and child health, postnatal care). AGYW receiving reproductive health-related services through OPD, or other departments are eligible. AGYW receiving reproductive health-related services through other departments are eligible. Willing and able to partake in an informed consent process. Able to speak and read in Kiswahili or English.
Where it's running
-
Kenya Medical Research Institute and Partners in Health & Research Development
Thika, Kiambu County, Kenya Recruiting
Study contacts
- Principal investigator: Nelly Mugo, MBChB, MMed, MPH — Kenya Medical Research Institute
- Study coordinator: Renee Heffron, PhD, MPH
- Email: rheffron@uabmc.edu
- Phone: 205-934-7349
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Project SHIELD 2.0: Police Education to Support Public Health in Kentucky
Aimed at police in Kentucky, this program tests whether SHIELD training given to officers, with health workers helping deliver it, can reduce drug-related arrests and steer people who use drugs toward MOUD and other health services.
-
New ways to diagnose lymphoma and multicentric Castleman disease in people living with HIV
This study tests a quick, point-of-care nucleic acid test to help diagnose lymphoma and multicentric Castleman disease in people living with HIV in sub-Saharan Africa.
-
Bridge to Belonging: A Peer‑Led Program to Reduce Loneliness and Depression in older gay and bisexual men with HIV
This program tests a peer-delivered, manualized approach to help men aged 50+ with HIV connect to LGBTQ+-affirming elder services to see if it reduces loneliness and depressive symptoms.
-
HIV vaccine test in healthy adults using CH505 nanoparticles and mRNA boosters
This early-stage study will test the safety and immune responses of CH505 vaccine regimens in healthy adults to see if they can trigger HIV-specific immune protection.
-
Stigma-reducing program to help women who use drugs stay in HIV care
This test checks whether a stigma-reduction program helps women living with HIV who use drugs stay engaged in HIV care in Ukraine.
-
Platelets and HIV Reservoirs: A look at how platelets might harbor HIV in people living with HIV
This observational study tests whether HIV can be found inside platelets in adults with suppressed HIV on therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.